Clinical Research
corporate_fare

Exo Biologics

Address
Boulevard Gustave-Kleyer 17

Sponsor Overview

assignment
1
sponsored trial
science
2
molecules
location_city
11
research centres
public
2
countries
person_search
11
investigators

Specializations

Neonatal respiratory medicine

Exo Biologics focuses on bronchopulmonary dysplasia in extremely preterm newborns, with research centered on respiratory outcomes in the neonatal intensive care setting.

  • Bronchopulmonary dysplasia
  • Preterm infant lung disease
  • Neonatal respiratory support

The sponsor’s activity is directed toward early-life lung injury and the prevention of chronic respiratory complications in vulnerable newborns.

Cell-derived biologic therapies

The clinical program includes mesenchymal-derived extracellular vesicles as an investigational biologic approach, reflecting interest in regenerative medicine and cell-free therapies.

  • Extracellular vesicles
  • Mesenchymal-derived biologics
  • Regenerative neonatal therapy

These studies place emphasis on biologic interventions intended to support lung development and repair in the neonatal period.

Pulmonary protection and disease prevention

Research activity is aimed at reducing the development of grade II-III bronchopulmonary dysplasia, highlighting a preventive focus in pediatric pulmonology.

  • Prevention of chronic lung disease
  • Neonatal pulmonary protection
  • Respiratory morbidity reduction

The sponsor’s therapeutic interest lies in limiting progression to more severe respiratory impairment among high-risk newborns.

Intratracheal neonatal administration

The funded research involves intratracheal administration in newborns, indicating a clinical interest in direct pulmonary delivery for neonatal airway treatment.

  • Intratracheal delivery
  • Airway-targeted therapy
  • Early respiratory intervention

This area connects drug delivery considerations with the management of fragile infant lungs in the earliest stages of life.

Sponsored Trials

Trial Name Country Status
Phase I single arm, dose escalating and phase II double blind, randomized, placebo-controlled dose finding clinical trial assessing safety, and efficacy of intratracheal administration of allogeneic umbilical mesenchymal cells-derived extracellular vesicles in preventing bronchopulmonary dysplasia in extremely preterm newborns.Belgium BelgiumItaly ItalyRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 11 sites collaborated multiple times

This sponsor has worked with 11 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Respiratory Tract Diseases1 trial
    277 other sponsors

Partnered Research Centres

11 centres
location_city
assignment191
Az St-Jan Brugge-Oostende A.V.
Address
Ruddershove 10, 8000 Bruges
Learn morearrow_forward
location_city
assignment392
Azienda Ospedaliera di Padova
Address
Via Nicolo' Giustiniani 2, 35128 Padua
Learn morearrow_forward
location_city
assignment624
Azienda Ospedaliero Universitaria Careggi
Address
Largo Giovanni Alessandro Brambilla 3, 50134 Florence
Learn morearrow_forward
location_city
assignment349
Azienda Ospedaliero Universitaria Di Modena
Address
Largo Del Pozzo 71, 41124 Modena
Learn morearrow_forward
location_city
assignment3
CHC
Address
Rue De Hesbaye 75, 4000 Liège
Learn morearrow_forward
location_city
assignment687
Cliniques Universitaires Saint-Luc
Address
Hippokrateslaan 10, Batiment 54, 1200 Woluwe-Saint-Lambert
Learn morearrow_forward
Page 1 of 2

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Exo Biologics.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.